Minerva Surgical (UTRS) Stock Price

Minerva Surgical Price

NASDAQ·CLOSED
0.00
​
Market closed

Over the last 4 years Minerva Surgical grew revenue by 53.9% annually, reaching 47.30 M USD. For Minerva Surgical, the net margin of -70.7% is up versus -617.2% a few years ago.

Minerva Surgical stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical business model & stock analysis

Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options.

Frequently asked questions about Minerva Surgical

7 analysts currently rate the Minerva Surgical stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Minerva Surgical to generate revenue of 70.78 M USD and earnings per share of -1.19 USD.

Converted at the current exchange rate, the Minerva Surgical share trades at 0.00 EUR (0.00 USD).

The Minerva Surgical share (UTRS) is listed on 1 stock exchanges, including: NASDAQ (UTRS).

The expected revenue of Minerva Surgical is 70.78 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Minerva Surgical is -10.54 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Minerva Surgical is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Minerva Surgical stock.

The price-to-sales ratio (P/S) of Minerva Surgical is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Minerva Surgical stock.

The Eulerpool Quality Score for Minerva Surgical is 5/10.

The ISIN of Minerva Surgical is US60343F2056. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Minerva Surgical is UTRS. The ticker symbol is used to trade Minerva Surgical shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
301,261.15 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 22, 2021
ISIN
US60343F2056
Cusip
60343F106
Sedol
BMG9GF1
Market capitalization
888.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2024
—
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-59.98 %
Last updated Nov 1, 2026, 12:16 AM

Minerva Surgical Peer Group

Minerva Surgical Ticker

NASDAQ · UTRS